Breast tumors lacking expression of human epidermal growth factor receptor 2 (HER2) and the estrogen and the progesterone receptors (triple negative; TNBC) are more aggressive than other disease subtypes, and no molecular targeted agents are currently available for their treatment. Because TNBC commonly displays EGF receptor (EGFR) expression, and combinations of monoclonal antibodies to EGFR effectively inhibit other tumor models, we addressed the relevance of this strategy to treatment of TNBC. Unlike a combination of the clinically approved monoclonal antibodies, cetuximab and panitumumab, which displaced each other and displayed no cooperative effects, several other combinations resulted in enhanced inhibition of TNBC's cell growth both in vitro and in animals. The ability of certain antibody mixtures to remove EGFR from the cell surface and to promote its intracellular degradation correlated with the inhibitory potential. However, unlike EGF-induced sorting of EGFR to lysosomal degradation, the antibody-induced pathway displayed independence from the intrinsic kinase activity and dimer formation ability of EGFR, and it largely avoided the recycling route. In conclusion, although TNBC clinical trials testing EGFR inhibitors reported lack of benefit, our results offer an alternative strategy that combines noncompetitive antibodies to achieve robust degradation of EGFR and tumor inhibition.
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cancer therapy | signal transduction G rowth factors and their transmembrane receptor tyrosine kinases play critical roles in tumor progression (1) . One remarkable example entails a large family of growth factors, all sharing an EGF motif, and their respective receptor tyrosine kinases of the EGFR family. Consistent with essential roles in tumor progression, strategies able to interfere with ERBB functions, such as mAbs and tyrosine kinase inhibitors (TKIs), have yielded in the past decade several oncology drugs (2) . For example, two genetically engineered mAbs to EGF receptor (EGFR), cetuximab and panitumumab, are approved for treatment of colorectal cancer. Unlike TKIs' well-understood mode of action, the mechanisms underlying therapeutic activities of mAbs are less understood. In general, potential mechanisms can be divided into immune-mediated cell killing, such as antibody-dependent cellular cytotoxicity, and diverse neutralizing effects, such as inhibition of ligand binding, prevention of receptor dimerization, and induction of receptor internalization (3) . Early animal studies that tested a set of mAbs to the rodent form of ERBB2/human epidermal growth factor receptor 2 (HER2) indicated that individual mAbs cause partial tumor eradication, whereas the administration of certain mixtures of antibodies resulted in synergistic effects (4) . Similar effects on the human HER2 protein were later confirmed (5, 6) . In vitro, the more effective mAb mixture was also more effective than the single mAbs in inducing receptor degradation (6) and antibody-dependent cellular cytotoxicity (5) . Synergistic antitumor effects were confirmed and associated with receptor degradation using another set of mAbs to HER2 (7) . Importantly, a mixture of two mAbs to HER2, trastuzumab and pertuzumab, in combination with chemotherapy, significantly prolonged progression-free survival of breast cancer patients whose tumors overexpress HER2 (8) . Similar to anti-HER2 mAbs, cetuximab induces down-regulation of EGFR, and this effect appears important for growth inhibition (9) . Experiments that used a radiolabeled cetuximab confirmed endocytosis of the mAb, but the internalized mAb recycled more effectively than internalized EGF (10) . In similarity to the synergistic internalizing effects of combinations of HER2-directed mAbs, we noted that certain pairs of anti-EGFR antibodies can accelerate receptor endocytosis and degradation (11) . To enhance endocytosis, the mAbs must engage nonoverlapping antigenic epitopes of EGFR. Another study showed that highly potent mAb combinations reduced surface receptor levels through a mechanism consistent with mAb-mediated inhibition of EGFR recycling (12) .
The ability of certain mAb mixtures to enhance EGFR degradation raised the possibility that such a strategy would inhibit EGFR-driven tumors, including the most aggressive fraction of breast cancer, which is defined by absence of estrogen receptor, progesterone receptor, and HER2 (13) . A subclass of triple negative breast cancer (TNBC) overexpresses EGFR (14) , and exhaustive gene expression profiling identified several EGFRassociated poor prognostic signatures (15) . Contrary to other breast cancer subtypes, for which therapy targeting biological drivers proved to be successful, no molecular targeted agents are approved for TNBC. Importantly, kinase inhibitors and anti-EGFR therapy using a single mAb did not improve outcome of TNBC (16) . For these reasons, it is imperative to develop new strategies able to control TNBC and delay the onset of patient resistance to chemotherapy. Here we characterize the mechanism of mAb-induced EGFR internalization and demonstrate that a cooperative mAb mixture can inhibit growth of TNBC in animals.
Results
Certain Combinations of Anti-EGFR mAbs Enhance Receptor DownRegulation. Certain combinations of epitope-distinct anti-HER2/ ERBB2 antibodies induce receptor endocytosis and synergistically inhibit growth of HER2-overexpressing tumor cells (7) . To identify similar pairs of anti-EGFR mAbs, we incubated MDA-MB-468 TNBC cells with a fluorescent derivative of EGF in the presence of anti-EGFR mAbs 111, 565, panitumumab, and cetuximab. Three of the four antibodies effectively displaced EGF, but mAb565 behaved as a relatively weak competitor (Fig. 1A) . Next, we radiolabeled panitumumab and found that the two clinically approved antibodies share antigenic epitopes and therefore they may not synergize; however, mAb565 engages a distinct epitope of EGFR ( Fig. S1 A and B) . Similar analyses revealed that mAb111 binds EGFR independently from the binding of cetuximab and panitumumab ( Fig. 1 B and C) , and according to our previous report, mAbs 111 and 565 are noncompetitive (11) . These lines of evidence excluded the panitumumab plus cetuximab pair and have identified several combinations (e.g., 111/panitumumab and 111/ cetuximab) as potential collaborative pairs. A standard EGFR down-regulation assay, performed with HeLa cells, validated these predictions ( Fig. 1D ): long-term exposure to the noncompetitive mAb combinations achieved receptor down-regulation. This was also confirmed by immunoblot analyses showing that receptor down-regulation closely reflected disappearance of the respective protein band (Fig. 1E) . Interestingly, mAb565 induced more extensive down-regulation of EGFR, an activity we attribute to a faint ability to stimulate auto-phosphorylation (Fig. 1E) . Similarly, exposure of HeLa cells to either mAb111 or panitumumab induced weak auto-phosphorylation, but their combination strongly induced both phosphorylation and down-regulation (Fig. 1F ). In conclusion, the ability of mAbs to down-regulate EGFR correlates with the engagement of nonoverlapping sites.
When Combined, Noncompetitive mAbs Induce EGFR Ubiquitination.
Because EGF-induced ubiquitination of EGFR by c-CBL E3 ligase is tightly associated with receptor degradation (17), we tested receptor ubiquitination after treatment with the panitumumab plus mAb111 pair. Unlike single mAbs, the combined treatment increased EGFR ubiquitination ( Fig. 2A) . As expected, EGF-induced ubiquitination appeared earlier and, interestingly, yielded a mixture of higher molecular weight species. Another difference emerged from a coimmunoprecipitation experiment: Unlike the well-characterized EGF-induced formation of EGFR-CBL complexes, neither a single mAb nor a combination resulted in detectable complexes (Fig. 2B) . Nevertheless, both EGF-and mAb-induced EGFR degradation were inhibited by a blocker of lysosomal hydrolases (bafilomycin), but an antagonist of the 26S proteasome (bortezomib) was ineffective (Fig. 2C) . Conceivably, mAb mixtures accelerate lysosomal degradation by inducing relatively slow ubiquitination of EGFR and recruiting an E3 ligase distinct from c-CBL.
The wealth of information on EGF-induced receptor degradation contrasts with the paucity of data on mAb-induced endocytosis. Hence, we screened a library of siRNAs arranged in 180 pools, each targeting a single endocytic mediator (Materials and Methods). HeLa cells were transfected with individual pools, along with control siRNAs. Thereafter, cells were treated with a mAb mixture and incubated for 12 h before analysis of EGFR degradation. A validation test and a list of positive hits (in two cycles) are depicted in Fig. S2 . Remarkably, two proteins that play critical roles in clathrin-mediated endocytosis, Huntingtin interacting protein 1 (HIP1) and dynamin 2, a GTPase, scored positively. In addition to the dynamin's partner, amphiphysin, and the ubiquitin binder EPS15L1, the screen identified several proteins involved in late stages of the endocytic pathway, such as RAB7L1 (18) and TSG101. These observations are consistent with a model assuming that mAb combinations divert EGFR from the recycling route to late endosomes and lysosomes (12) .
Antibody-Induced Endocytosis of EGFR Avoids the Recycling
Compartment. To examine a scenario of mAb-mediated inhibition of recycling, we analyzed subcellular distribution of EGFR. As predicted, treatment with a mAb mixture translocated EGFR of HeLa cells into intracellular vesicles (Fig. S3) . Although EGF induced a similar translocation, treatment with single mAbs was ineffective. These differences were quantified using flow cytometry ( Fig. 3 A and B) : incubation with either EGF or two mAbs increased the intracellular fraction. To directly follow the recycling route, we used an antibody to RAB11, a GTPase of recycling endosomes (18) . As expected, in untreated cells, EGFR and RAB11 displayed nonoverlapping patterns, but EGF translocated the receptor to the perinuclear recycling compartment (Fig. 3C) . Importantly, although the mAb mixture extensively translocated EGFR into intracellular puncta, these structures were devoid of RAB11, which is in line with the possibility that mAb mixtures sort EGFR for degradation while avoiding the recycling route.
mAb-Induced Degradation of EGFR Is Independent of the Kinase
Activity and the Intrinsic Dimerization Ability of EGFR. Because of their ability to force EGFR dimerization, antibodies might act as partial agonists. To examine this, we probed extracts of stimulated HeLa cells. As expected, EGF enhanced phosphorylation of EGFR as well as phosphorylation of two effectors, AKT and ERK (Fig. 4A) . Remarkably, although the agonist antibody 565 and mixtures of noncompetitive mAbs enhanced EGFR auto-phosphorylation as well as accelerated receptor degradation, this did not translate to ERK or AKT activation. Hence, we assumed that mAb-mediated and EGF-induced dimerization differ. Next, we used a previously described EGFR mutant that is defective in both homodimer formation and EGF-induced internalization (19) . Using this deletion mutant (ΔCR1), we confirmed that dimerization is essential for both EGF-induced auto-phosphorylation and degradation of EGFR (Fig. 4B) . Strikingly, neither mAb-mediated autophosphorylation nor mAb-mediated degradation of EGFR displayed dependence on the intrinsic dimer-forming ability of EGFR, implying that mAb-induced clustering preempts the intrinsic dimer-forming feature of EGFR. The EGFR-specific TKI, AG1478, was used in an effort to clarify the contribution of the intrinsic kinase activity to mAbinduced endocytosis. Although treatment with AG1478 completely blocked both EGF and mAb-induced auto-phosphorylation, only the ligand-induced degradation of EGFR was inhibited (Fig. 4C) . Node-positive TNBC is associated with higher EGFR expression compared with node-negative lesions (20) , suggesting that EGFR drives tumor progression. As a prelude to testing the applicability of mAb-mediated down-regulation, we surveyed EGFR status in a series of TNBC cell lines (Fig. S4A ). This analysis confirmed EGFR overexpression in TNBC cell lines; lines that belong to other subtypes, such as HER2 + (SKBR3 and T47D) and the luminal type (MCF7), displayed lower EGFR levels. Next, we transfected BT-549 TNBC cells with EGFR-specific siRNAs (Fig.  S4B ) and found that loss of >80% of the receptor associated with 60% or 80% reduction in the ability of cells to migrate or invade through an extracellular barrier, respectively (Fig. S4 C  and D) . Next, we asked whether a similar effect would accompany A B C Fig. 2 . Anti-EGFR antibodies enhance receptor ubiquitination and degradation. (A) Serum-starved HeLa cells were incubated with mAbs (10 μg/mL), a combination (each at 5 μg/mL), or with EGF (10 ng/mL), and lysates analyzed using immunoprecipitation (IP) and immunoblotting (IB). (B) HeLa cells transfected with a plasmid encoding an MYC peptide-tagged CBL, or an empty vector, were serum-starved and treated for 3 h with the indicated mAbs (20 μg/mL) or a combination (each at 10 μg/mL). Alternatively, cells were treated for 10 min with EGF (10 ng/mL). Lysates were probed as indicated. (C) HeLa cells that were preincubated (12 h) with bortezomib (2 μM) or bafilomycin (10 nM) were incubated (60 min) with EGF (10 ng/mL) or for 6 h with the indicated combination of mAbs (each at 10 μg/mL). Lysates were subjected to IB and signal quantification. Thereafter, cells were permeabilized and EGFR was localized using flow cytometry. EGFR distribution between the plasma membrane (scored as 1) and the cell's center (scored as 0) was assessed. (C) HeLa cells were treated with EGF (10 ng/mL; 30 min) or mAbs (10 μg/mL total; 4 h). Following fixation, permeabilization, and incubation with anti-EGFR and anti-Rab11 antibodies, cells were incubated with fluorescent secondary antibodies, and images were acquired with a confocal fluorescent microscope. Colocalization of two markers appears as yellow (Merge).
mAb-induced endocytosis. Using a set of TNBC cell lines and mAb mixtures, we observed EGFR down-regulation (Fig. 5A) , similar to the effects on HeLa cells (Fig. 1D) . When singly applied, mAbs other than the partial agonist, 565, were unable to down-regulate EGFR, but mixtures of noncompetitive mAbs caused EGFR degradation in all tested TNBC lines. Notably, EGF was unable to down-regulate EGFR of MDA-MB468 cells, probably because of saturation of the endocytic pathway by the highly expressed receptor (21) . Nevertheless, reproducible downregulation was achieved by mAbs, in line with distinct routes of endocytosis engaged by mAbs and EGF.
Next, we tested the prediction that mAb combinations would inhibit migration of TNBC cells. For this, we used BT-549 cells and a mAb combination that effectively down-regulated EGFR (Fig. 5B) . Under these conditions, we observed almost 50% reduction in cell migration, but neither mAb, when singly applied, was effective (Fig. 5 C and D) . These findings are consistent with the observations we made using siRNAs specific to EGFR (Fig.   S4 ). In conclusion, EGFR appears to play an important role in the migratory behavior of the TNBC model we used, such that mAb-induced endocytosis and degradation of EGFR can significantly limit cell migration in vitro.
Mixtures of mAbs Arrest TNBC Cells at G1 and Inhibit Their Tumorigenic
Growth in Animals. Prolonged exposure of HCC70 cells to cetuximab, or to cetuximab plus mAb565, exerted only minor effects on cell survival, as reflected by the unchanged sub-G1 fraction (Fig.  S5A) . In contrast, exposure to an apoptosis-inducing drug, puromycin, increased sub-G1 and erased the S-phase fraction, consistent with up-regulation of the cleaved form of caspase-3 (Fig.  S5B) . Although the mAbs induced no detectable apoptosis, they clearly arrested cells at G1 (Fig. S5A) . To measure proliferation, HCC70 cells were incubated for 5 d with another pair of noncompetitive mAbs (Fig. 6A) . This prolonged incubation took place in serum-free medium that was supplemented, or not, with EGF. Although EGF strongly promoted proliferation of HCC70 cells, this effect was almost completely inhibited by the combination of mAbs. Notably, each antibody exerted only a small inhibitory effect when singly applied, in line with the proposed effect of antibody-induced endocytosis of EGFR.
Animal studies using HCC70 cells examined the relevance of our observations to tumor growth. Cells were injected intradermally; once tumors became palpable, we injected into the peritoneum either single mAbs or mAb combinations. Fig. 6 B and C presents the results: differences emerged following 4 wk of tumor growth-each mAb induced a partial inhibitory effect, but the combinations more effectively regressed tumors (see also Fig. S6) . Importantly, the inhibitory effects progressively increased, such that the cetuximab plus mAb111 combination reached statistical significance (P < 0.01) at week 8, and the other combination clearly showed a similar trend at the time of trial termination.
In summary, although TNBC clinical trials using EGFR inhibitors, including cetuximab, reported lack of clinical benefit (22), our results offer an alternative strategy. This strategy combines noncompetitive mAbs to achieve robust EGFR degradation. Similar to EGF, noncompetitive mAbs target EGFR to degradation in lysosomes and engage ubiquitination and the clathrin-mediated route. Nevertheless, mAb-induced degradation is unique and identifies oligoclonal mixtures as a viable alternative to the singly used therapeutic mAbs: this relatively slow process is independent of c-CBL and the intrinsic kinase activity, or dimer-forming ability, of EGFR. As a result, mAb mixtures inhibit motility of TNBC cells as well as arrest them at G1, attributes that translate to effective inhibition of tumor growth in an animal model.
Discussion
Several lines of evidence support the possibility that EGFR plays a driver role in a large fraction of TNBC. For example, EGFR gene amplification is commonly identified in metaplastic breast carcinoma, a basal-like fraction of tumors (14) . Likewise, gene expression signatures correlated TNBC with modules comprising EGF-like ligands, EGFR, and several downstream effectors (15) . In an effort to examine the proposition that agents intercepting EGFR bear therapeutic potential for TNBC, we examined mixtures of anti-EGFR mAbs. Because their antigenic epitopes are overlapping, combining cetuximab and panitumumab, the EGFcompetitive anti-EGFR monoclonals routinely used to treat colorectal cancer patients, did not improve receptor degradation. Importantly, the percentage of patients responding to these antibodies is low and many patients experiencing an initial response eventually relapse. Whether or not mAbs selected on the basis of their ability to accelerate EGFR degradation will increase response rate or delay the onset of patient resistance remains an open issue. An answer to this question might be provided by current clinical trials applying Sym004, a mixture of two noncompetitive anti-EGFR antibodies, on both squamous cell carcinoma of the head and neck and metastatic colorectal cancer (23) .
Additional combinations of anti-EGFR antibodies can accelerate receptor degradation, and the underlying mechanism appears related to the sorting of internalized EGFRs to either recycling or degradation (12) . In the case of EGF-stimulated EGFRs, sorting requires conjugation of multiple ubiquitins, which mark the receptor for degradation (24) . By applying a mixture of mAbs, we detected relatively slow EGFR ubiquitination and degradation (Fig. 2) . Despite similarities, the mechanisms underlying sorting of EGFR by mAb mixtures and by EGF remarkably differ: EGF robustly increases receptor phosphorylation, which is necessary for recruitment of an E3 ubiquitin ligase of the CBL family (17) , but antibody mixtures behave as very weak agonists of auto-phosphorylation, and we could not detect recruitment of c-CBL. Importantly, mAb-induced receptor ubiquitination is associated with avoidance of the recycling route (Fig. 3D) ; consistent with this observation, siRNA screens implicated two components of late endosomes, RAB7 and TSG101, along with early mediators such as clathrin and dynamin, in mAb-induced receptor sorting. Although this ensemble of endocytic players outlines a clathrin-mediated route, it is interesting noting that knocking down HIP1, an endocytic actin-binding protein, severely impaired antibody-induced degradation of EGFR (Fig. S2) .
Conceivably, the robust antibody-induced down-regulation of EGFR employs more than one intracellular route to target surface EGFRs to lysosomes, such as actin-dependent micropinocytosis or a clathrin-independent route (25) . Our subsequent experiments, which used several TNBC lines, indicated that downregulation of EGFR can retard motility, signaling, and proliferation of different TNBC cell lines. These observations were supported by animal studies demonstrating that antibody mixtures can reduce the tumorigenic growth of TNBC cells. Thus, regardless of the exact mechanisms underlying the cooperative effect of antibody mixtures, the studies we presented offer a therapeutic scenario to treat a rather heterogeneous and therapy-resistant type of breast cancer (13) . . Thereafter, cells were plated in the upper compartment of invasion chambers. The lower compartments were filled with the respective mAb-containing media. Eighteen hours later, the filters were removed, fixed, permeabilized, and stained with methyl violet (0.3%). Cells growing on the upper side of the filter were removed and cells on the bottom side were photographed and quantified.
chambers. The lower compartment was filled with serum-containing medium. Eighteen hours later, cells on the lower side of the filter were fixed, permeabilized with Triton X-100 (0.1%), and stained with crystal violet. Images were quantified by using ImageJ.
Tumorigenic Growth in Animals. All animal studies were approved by the Weizmann Institute's Review Board (IRB). CD1/nude mice were divided in groups of five mice and injected intradermally with HCC70 cells (7 × 10 6 per mouse). mAbs were injected intraperitoneally at 160 μg per mouse per injection on days 7, 14, 21, 28, and 35 after grafting. Tumor volume was evaluated once per week.
ImageStream Analysis. Following treatments, cells were trypsinized, fixed, permeabilized, and stained with an anti-EGFR antibody and a secondary antirabbit antibody. A total of 10,000 events from each sample were collected using the ImageStreamX instrument (Amnis Corp.) and IDEAS 4.0 software. Single cells were gated using the area and aspect ratio features as well as the Gradient RMS feature (26) . Cells were then gated to select only positively stained cells using their pixel intensity values. The localization of EGFR was calculated using the Max Contour Position feature.
Statistical Analysis. Two-way ANOVA and Bonferroni multiple comparison tests were used to analyze differences between groups. P values < 0.01 were considered significant. Groups of five CD1/nude mice were injected intradermally with 7 × 10 6 HCC70 cells. Antibodies (total: 160 μg/animal/injection) were weekly injected intraperitoneally once tumors became palpable. Tumor volumes were assessed once per week. **P < 0.01 by two-way analysis of variance with Bonferroni's multiple comparison posttests. The average tumor size in each group ± SEM is presented.
